What is OM1?
OM1 specializes in delivering AI-powered, real-world data and insights designed to enhance personalized medicine and observational research. By offering tech-enabled solutions for both prospective and retrospective evidence generation, the company addresses complex challenges in immunology, mental health, and cardiometabolic health. Recognized with the Frost & Sullivan Award for New Product Innovation in RWE Analytics, OM1 leverages extensive data networks to assist global healthcare organizations in improving patient outcomes. The company's platform is engineered to transform fragmented health data into structured, high-fidelity cohorts, providing a robust foundation for pharmaceutical and clinical research stakeholders to optimize their therapeutic strategies.
How much funding has OM1 raised?
OM1 has raised a total of $171M across 4 funding rounds:
Series A
$15M
Series B
$21M
Private Equity
$50M
Other Financing Round
$85M
Series A (2017): $15M with participation from 7wireVentures, Wanxiang Healthcare Investments, and General Catalyst
Series B (2018): $21M led by General Catalyst, 7wireVentures, and Polaris Partners
Private Equity (2019): $50M supported by BA Venture Partners, Polaris Partners, General Catalyst (GC), and 7wireVentures
Other Financing Round (2021): $85M featuring D1 Capital Partners, Breyer Capital, and Kaiser Permanente
Key Investors in OM1
General Catalyst
General Catalyst is a venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors, leveraging deep operational experience to help companies achieve substantial scale.
7wireVentures
7wire Ventures builds and invests in early-stage digital health companies, focusing on creating informed and connected health consumers through innovative AI and personalized coaching solutions.
Polaris Partners
Polaris Partners is a venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors, providing strategic coaching and resources to foster long-term innovation.
What's next for OM1?
With the support of its latest capital injection, OM1 is well-positioned to accelerate its enterprise-level growth and expand its data network capabilities. The company is expected to focus on deepening its analytical prowess in high-acuity specialty areas, ensuring that its RWE solutions remain at the forefront of the digital health revolution. As the healthcare industry increasingly shifts toward value-based care, OM1's ability to provide granular, longitudinal patient data will be instrumental in driving clinical innovation. Future strategic initiatives will likely involve scaling its operational footprint and enhancing its AI-driven predictive modeling to meet the evolving demands of global life sciences partners.
See full OM1 company page
